Tarsus Pharmaceuticals, Inc. (TARS)
| Market Cap | 3.27B +18.8% |
| Revenue (ttm) | 606.33M +105.2% |
| Net Income | -46.48M |
| EPS | -1.08 |
| Shares Out | 43.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,001 |
| Open | 74.48 |
| Previous Close | 74.46 |
| Day's Range | 72.94 - 75.26 |
| 52-Week Range | 53.89 - 91.53 |
| Beta | 0.45 |
| Analysts | Strong Buy |
| Price Target | 99.50 (+33.59%) |
| Est. Earnings | Nov 3, 2026 |
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner ... [Read more]
Financial Performance
In 2025, Tarsus Pharmaceuticals's revenue was $451.36 million, an increase of 146.71% compared to the previous year's $182.95 million. Losses were -$66.42 million, -42.52% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price target is $99.5, which is an increase of 33.59% from the latest price.
News
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it expects to present 11 scientific abstracts at the American Academy of Optometry (...
Tarsus Pharmaceuticals resumed with a Buy at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Tarsus Pharmaceuticals (TARS) with a Buy rating and $116 price target Goldman resumed coverage of the biotechnology sector, saying the group ha...
Tarsus Pharmaceuticals reinstated with an Overweight at Barclays
Barclays reinstated coverage of Tarsus Pharmaceuticals (TARS) with an Overweight rating and $110 price target following the close of the Alkeus deal. The firm says its more bullish view on…
Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies
Jefferies raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $105 from $88 and keeps a Buy rating on the shares. The firm notes the stock has rallied post…
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approv...
Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease
Daily treatment with oral gildeuretinol met the primary endpoint and resulted in a statistically significant reduction in the growth rate of retinal atrophic lesions compared to untreated group. Gilde...
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences: Wells Fargo...
Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease
CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today annou...
Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $100 from $97 and keeps an Outperform rating on the shares. The firm is updating its…
Tarsus Pharmaceuticals price target raised to $100 from $98 at Mizuho
Mizuho raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $100 from $98 and keeps an Outperform rating on the shares.
Tarsus to acquire Alkeus Pharmaceuticals for $450M upfront, up to $800M total
Tarsus Pharmaceuticals (TARS) announced that it has entered into a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gil...
Tarsus Pharmaceuticals reports Q2 EPS (43c), consensus (20c)
Reports Q2 revenue $173.91M, consensus $169.51M. “XDEMVY delivered another record quarter, reflecting strong underlying demand and commercial execution,” said Bobby Azamian, Chief Executive Officer an...
Tarsus Pharmaceuticals announces $125M private placement
Tarsus Pharmaceuticals (TARS) announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public...
Tarsus Pharmaceuticals Earnings Call Transcript: Q2 2026
XDEMVY delivered strong Q2 growth with $173.9M in sales, driving updated full-year guidance. The acquisition of Alkeus adds ALK-001, a late-stage therapy for Stargardt disease, expanding the retina pipeline and long-term growth prospects.
Tarsus Pharmaceuticals Earnings release: Q2 2026
Tarsus Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tarsus Pharmaceuticals Quarterly report: Q2 2026
Tarsus Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tarsus Pharmaceuticals Slides: Q2 2026
Tarsus Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Eye drug maker Tarsus Pharmaceuticals said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million, adding an experimental oral therapy fo...
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Generated second quarter 2026 XDEMVY ® net product sales of $173.9 million, an increase of more than 69% year-over-year
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified...
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the...
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m.
Tarsus Pharmaceuticals price target lowered to $98 from $100 at Mizuho
Mizuho lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $98 from $100 and keeps an Outperform rating on the shares. The firm updated models in the smid-cap biotechnology…
Tarsus Pharmaceuticals price target lowered to $98 from $100 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $98 from $100 and keeps an Outperform rating on the shares.
Tarsus Pharmaceuticals price target lowered to $89 from $90 at Guggenheim
Guggenheim lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $89 from $90 and keeps a Buy rating on the shares. The firm is revising some of its estimates…